Tafluprost/timolol now available as combined glaucoma treatment

Taptiqom is a fixed-dose combination of the prostaglandin analogue tafluprost and the beta-blocker timolol, for the treatment of glaucoma.

The recommended dose of Taptiqom is one drop into the affected eye(s) once daily. | iStock
The recommended dose of Taptiqom is one drop into the affected eye(s) once daily. | iStock

Taptiqom is indicated for the reduction of intraocular pressure (IOP) in adults with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical monotherapy with beta blockers or prostaglandin analogues and require a combination therapy. It is presented as preservative-free eye drops in single-dose containers.

Tafluprost and timolol reduce intraocular pressure by complementary mechanisms of action.

IOP reduction

Further information
View Taptiqom drug record 
Summary of Product Characteristics
Manufacturer: Santen UK

Two 6-month, randomised, double-blind, phase III studies compared the safety and efficacy of the preservative-free fixed combination of tafluprost 15 microgram/ml and timolol 5mg/ml with those of the two drugs as single agents or as a non-fixed combination in patients with open-angle glaucoma or ocular hypertension.

In the first study (n=400), mean diurnal IOP decreases from baseline ranged from -7.3 to -9.1 mmHg (29.6–34.6%) with the fixed combination and from -7.5 to -9.4 mmHg (30.7–36.0%) with the non-fixed combination (p<0.0001 vs="" baseline="" for="" both="" an="" iop="" decrease="" of="" at="" least="" 30="" was="" achieved="" in="" 58="" 3="" and="" 66="" 9="" the="" patients="" fixed-combination="" non-fixed-combination="" groups="" respectively="" p="" all="" measures="" reduction="" fixed="" tafluprost="" timolol="" combination="" were="" statistically="" clinically="" significant="" non-inferior="" to="" those="" non-fixed="">

In the second study, 564 patients whose condition was inadequately controlled on timolol or prostaglandin monotherapy for 6 months received timolol, tafluprost or the fixed tafluprost/timolol combination.

Average diurnal IOP change from baseline at month 3 was 32–33% for patients who received the combination, 28% for those treated with timolol and 28% for those who received tafluprost. The treatment difference was significant for the combination versus both timolol (p=0.044) and tafluprost (p<0.001), indicating superiority to both monotherapies.


The most common adverse effect of the tafluprost/timolol combination was conjunctival hyperaemia, which occcured in approximately 7% of patients.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in